You are here

  • Home
  • Archive
  • Volume 8, Issue Suppl 3
  • 212 CLEC-1 is a novel myeloid immune checkpoint for cancer immunotherapy limiting tumor cells phagocytosis and synergizing with tumor-targeted antibodies

Article metrics

Article menu

Download PDFPDF

Regular and young investigator award abstracts
Checkpoint blockade therapy
212 CLEC-1 is a novel myeloid immune checkpoint for cancer immunotherapy limiting tumor cells phagocytosis and synergizing with tumor-targeted antibodies

 

Online download statistics by month:

Online download statistics by month: November 2020 to June 2025

AbstractFullPdf
Nov 2020167023
Dec 20203307
Jan 20211603
Feb 20212604
Mar 20214009
Apr 20212003
May 2021307
Jun 2021006
Jul 2021007
Aug 2021007
Sep 2021006
Oct 202134022
Nov 202139023
Dec 20212605
Jan 20222301
Feb 20221605
Mar 20221107
Apr 20222806
May 202219012
Jun 20221806
Jul 2022400
Aug 20221003
Sep 20221804
Oct 20221804
Nov 20221804
Dec 20222603
Jan 20233005
Feb 20232801
Mar 20231401
Apr 20231601
May 20232804
Jun 20231202
Jul 2023805
Aug 20231603
Sep 20231604
Oct 20233007
Nov 20232404
Dec 20233002
Jan 2024402
Feb 20241002
Mar 20241804
Apr 20241602
May 20242601
Jun 20243201
Jul 20241203
Aug 20242002
Sep 20241602
Oct 20241405
Nov 20243608
Dec 20241609
Jan 202528018
Feb 2025607
Mar 2025008
Apr 2025004
May 2025006
Jun 2025003
Total11190313